Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "South East Asia Molecular Diagnostics Market by Offering (Reagents, Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, ISH, INAAT, Sequencing, Microarray), Application (HIV, Influenza, HPV, Oncology, Gene Testing), End User - Forecast to 2031" has been added to ResearchAndMarkets.com's offering.
The Southeast Asia molecular diagnostics market is anticipated to expand significantly, reaching USD 891.9 million by 2031 from USD 528.3 million in 2024, representing a compound annual growth rate (CAGR) of 7.8% within the forecast period. This growth trajectory is driven by factors such as an aging population, the rising prevalence of communicable and non-communicable diseases, and technological advancements in molecular diagnostics. Furthermore, increased healthcare spending across the region bolsters this market growth.
The market faces challenges due to the lack of uniform medical device regulations across Southeast Asian countries and the high costs associated with molecular diagnostic tests. However, opportunities arise from the burgeoning medical tourism industry in Southeast Asia and an increasing focus on companion diagnostics. These avenues are expected to present substantial growth potential for key market players. Nevertheless, a key challenge remains in the shortage of skilled professionals in the field.
Leading companies in the Southeast Asia molecular diagnostics market include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, among others. These companies are noted for their diverse product offerings and strategic developments aimed at enhancing their market presence between 2021 and 2024.
The market is segmented based on offerings, test types, technology, application, and geography. In terms of offerings, kits and reagents accounted for the largest market share in 2024, driven by the availability of a wide range of diagnostic reagents and consumables. For test types, laboratory tests lead the market due to their high accuracy and cost-effectiveness compared to point-of-care tests.
Technology-wise, the Polymerase Chain Reaction (PCR) segment holds the largest market share, attributed to its versatility and application in diagnostics. This growth was further accelerated during the COVID-19 pandemic due to increased testing capabilities in countries like Indonesia.
Application-wise, infectious diseases account for the most significant market share. The need for rapid, sensitive and specific testing methods to control communicable diseases drive demand in this segment. The timely diagnosis through molecular diagnostics is crucial for managing these diseases effectively.
Geographically, Singapore is projected to command the largest market share by 2024, followed by Indonesia and Vietnam. This is attributed to Singapore's advanced healthcare infrastructure, while Indonesia's market growth is driven by improvements in healthcare facilities and spending.
Key questions addressed in the report include identifying high-growth market segments, exploring historical and forecasted market sizes, and understanding major drivers, restraints, and opportunities in the market. Furthermore, the report discusses the competitive landscape, recent developments, and strategic moves by major and emerging players in the Southeast Asia molecular diagnostics market.
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Southeast Asia Molecular Diagnostics Market Assessment-by Offering
6. Southeast Asia Molecular Diagnostics Market Assessment-by Test Type
7. Southeast Asia Molecular Diagnostics Market Assessment-by Technology
8. Southeast Asia Molecular Diagnostics Market, by Application
9. Southeast Asia Molecular Diagnostics Market Assessment-by End User
10. Southeast Asia Molecular Diagnostics Market Assessment-by Country
11. Competitive Landscape
12. Company Profiles
- Illumina Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Hologic Inc. (U.S.)
- Sansure Biotech Inc. (China)
- Agilent Technologies Inc. (U.S.)
- Danaher Corporation (U.S.)
- Abbott Laboratories (U.S.)
- Qiagen N.V. (Netherlands)
- Xiamen Zeesan Biotech Co. Ltd. (China).
For more information about this report visit https://www.researchandmarkets.com/r/yuljt2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
